Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

This Pre-Solicitation opportunity was posted on July 17, 2008. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Manufacture of SS1P Drug Product

Closed
N02-RC-81023-74Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

General Info

Agency

N/A

Contract Value

$815,099

NAICS

541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Place of Performance

KENSINGTON, MD, 20850, USA

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

Presolicitation

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
Contacts1 person available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
Contacts
Odessa S HendersonContracting Officer

Full Description

Show more
The Laboratory of Molecular Biology, Clinical Immunotherapy Program of the National Cancer Institute intends to negotiate a contract on a sole-source basis with Advanced BioSciences Laboratories, Inc. of Kensington, Maryland. The contract is for the production of SS1P immunotoxin drug product and requisite drug stability programs for Phase II clinical trials to be carried out at NIH in the Clinical Center. It is expected to be a cost-reimbursement contract for a period of 2 years. This acquisition shall complete the production of this drug which was begun under contract HHSN2612000800007. Specifically, the contractor shall 1) monitor the drug product for identity, potency and safety using a stability program consisting of a panel of assays ; 2) complete cGood Manufacturing Process of several lots of SS1P drug product; 3) review completed results at each time point and compare them to stability specifications provided; (NOTE: As stability results become available at each time point, the contractor shall issue a Certificate of Analysis for the time point and submit it to NCI.); 4) deliver the drug substance in a single lot of a least 1 mg frozen SS1 (dsFv)-PE38. Advanced BioSciences Laboratories meets the requirements of the FAR 6.302-1(a)(2), in that they are the only responsible source that will satisfy the agencies requirements without significant cost in the loss of time and materials already invested in the development of this drug. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet all the requirements, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient details to allow the NCI to determine if it can meet the requirements of this synopsis. The estimated period of performance is September 2008 through September 2010. Numbered Note 22 applies. Collect calls will not be accepted.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS